<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2 DOSAGE AND ADMINISTRATION<BR>               <BR>                  VICTRELIS must be administered in combination with peginterferon alfa and ribavirin. The dose of VICTRELIS is 800 mg (four 200-mg capsules) three times daily (every 7 to 9 hours) with food [a meal or light snack] (see Table 1). Refer to the peginterferon alfa and ribavirin Package Inserts for instructions on dosing.<BR>                  The following dosing recommendations differ for some subgroups from the dosing studied in the Phase 3 trials [see Clinical Studies (14)]. Response-Guided Therapy (RGT) is recommended for most individuals, but longer dosing is recommended in targeted subgroups (e.g., patients with cirrhosis).<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           800 mg administered orally three times daily (every 7 to 9 hours) with food (a meal or light snack). (2)<BR>                           VICTRELIS must be administered in combination with peginterferon alfa and ribavirin. Initiate therapy with peginterferon alfa and ribavirin for 4 weeks, then add VICTRELIS to peginterferon alfa and ribavirin regimen. The duration of treatment is based on viral response, prior response status and presence of cirrhosis. (2)<BR>                           Refer to peginterferon alfa and ribavirin Package Inserts for specific dosing instructions. (2)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1	VICTRELIS/Peginterferon alfa/Ribavirin Combination Therapy: Patients Without Cirrhosis Who Are Previously Untreated or Who Previously Failed Interferon and Ribavirin Therapy<BR>                     <BR>                        <BR>                           Initiate therapy with peginterferon alfa and ribavirin for 4 weeks (Treatment Weeks 1â€“4).<BR>                           Add VICTRELIS 800 mg (four 200-mg capsules) orally three times daily (every 7 to 9 hours) to peginterferon alfa and ribavirin regimen after 4 weeks of treatment. Based on the patient's HCV-RNA levels at Treatment Week (TW) 8, TW12 and TW24, use the following guidelines to determine duration of treatment (see Table 1).<BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t1"><BR>                           <caption>Table 1 Duration of Therapy in Patients Without Cirrhosis Who Are Previously Untreated or Who Previously Failed Interferon and Ribavirin Therapy</caption><BR>                           <col width="20%" align="center" valign="middle"/><BR>                           <col width="20%" align="center" valign="middle"/><BR>                           <col width="20%" align="center" valign="middle"/><BR>                           <col width="40%" align="left" valign="bottom"/><BR>                           <thead><BR>                              <tr styleCode="Botrule"><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule" colspan="2" align="center">ASSESSMENT<footnote><BR>                                       <content styleCode="bold">TREATMENT FUTILITY</content><BR>                                       <br/>If the patient has HCV-RNA results greater than or equal to 100 IU/mL at TW12, then discontinue three-medicine regimen.<br/>If the patient has confirmed, detectable HCV-RNA at TW24, then discontinue three-medicine regimen.</footnote><BR>                                    <br/>(HCV-RNA Results<footnote>"Not Detected" refers to HCV-RNA assay results reported as "Target Not Detected" or "HCV-RNA Not Detected". In clinical trials, HCV-RNA in plasma was measured using a Roche COBAS<sup>&#174;</sup> TaqMan<sup>&#174;</sup> assay with a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL. See <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml> for a description of HCV-RNA assay recommendations.</footnote>)</th><BR>                                 <th styleCode="Lrule Rrule" align="center" rowspan="2" valign="middle">RECOMMENDATION</th><BR>                              </tr><BR>                              <tr><BR>                                 <th styleCode="Lrule"/><BR>                                 <th styleCode="Lrule" align="center">At Treatment Week 8</th><BR>                                 <th styleCode="Lrule Rrule" align="center">At Treatment Week 24</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" rowspan="2"><BR>                                    <content styleCode="bold">Previously Untreated Patients</content><BR>                                 </td><BR>                                 <td styleCode="Rrule">Not Detected</td><BR>                                 <td styleCode="Rrule">Not Detected</td><BR>                                 <td styleCode="Rrule">Complete three-medicine regimen at TW28.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Rrule">Detected</td><BR>                                 <td styleCode="Rrule">Not Detected</td><BR>                                 <td styleCode="Rrule" align="left"><BR>                                    <list listType="ordered"><BR>                                       <item>Continue all three medicines and finish through TW36; and then</item><BR>                                       <item>Administer peginterferon alfa and ribavirin and finish through TW48.</item><BR>                                    </list><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule" rowspan="2"><BR>                                    <content styleCode="bold">Previous Partial Responders or Relapsers<footnote ID="ft1b"><BR>                                          <content styleCode="italics">See <linkHtml href="#S14">Clinical Studies (14)</linkHtml><BR>                                          </content> for definitions of previous response to interferon and ribavirin therapy.</footnote><BR>                                    </content><BR>                                 </td><BR>                                 <td styleCode="Rrule">Not Detected</td><BR>                                 <td styleCode="Rrule">Not Detected</td><BR>                                 <td styleCode="Rrule">Complete three-medicine regimen at TW36.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule">Detected</td><BR>                                 <td styleCode="Rrule Botrule">Not Detected</td><BR>                                 <td styleCode="Rrule Botrule" align="left"><BR>                                    <list listType="ordered"><BR>                                       <item>Continue all three medicines and finish through TW36; and then</item><BR>                                       <item>Administer peginterferon alfa and ribavirin and finish through TW48.</item><BR>                                    </list><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="xmChange"><BR>                                       <content styleCode="bold">Previous Null Responders<footnoteRef IDREF="ft1b"/><BR>                                       </content><BR>                                    </content><BR>                                 </td><BR>                                 <td styleCode="Rrule">Detected or Not Detected</td><BR>                                 <td styleCode="Rrule">Not Detected</td><BR>                                 <td styleCode="Rrule">Continue all three medicines and finish through TW48.</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Consideration should be given to treating previously untreated patients who are poorly interferon responsive (as determined at TW4) with 4 weeks peginterferon alfa and ribavirin followed by 44 weeks of VICTRELIS 800 mg orally three times daily (every 7 to 9 hours) in combination with peginterferon alfa and ribavirin in order to maximize rates of SVR.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2	VICTRELIS/Peginterferon alfa/Ribavirin Combination Therapy: Patients with Cirrhosis<BR>                     <BR>                        Patients with compensated cirrhosis should receive 4 weeks peginterferon alfa and ribavirin followed by 44 weeks VICTRELIS 800 mg (four 200-mg capsules) three times daily (every 7 to 9 hours) in combination with peginterferon alfa and ribavirin. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     	2.3 Dose Modification<BR>                     <BR>                        Dose reduction of VICTRELIS is not recommended.<BR>                        <BR>                           If a patient has a serious adverse reaction potentially related to peginterferon alfa and/or ribavirin, the peginterferon alfa and/or ribavirin dose should be reduced or discontinued. Refer to the peginterferon alfa and ribavirin Package Inserts for additional information about how to reduce and/or discontinue the peginterferon alfa and/or ribavirin dose. VICTRELIS must not be administered in the absence of peginterferon alfa and ribavirin. If peginterferon alfa or ribavirin is permanently discontinued, VICTRELIS must also be discontinued.<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.4	Discontinuation of Dosing Based on Treatment Futility<BR>                     <BR>                        Discontinuation of therapy is recommended in all patients with 1) HCV-RNA levels of greater than or equal to 100 IU per mL at TW12; or 2) confirmed detectable HCV-RNA levels at TW24.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>